Study of Clinical Efficacy and Safety of Tosedostat in MDS (IST-CTI-MDS) | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02452346

Study of Clinical Efficacy and Safety of Tosedostat in MDS (IST-CTI-MDS)
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

Study WCMC IST-CTI-MDS evaluates the safety and tolerability of tosedostat in adult patients with pathologically confirmed MDS (< 20% blasts in bone marrow, peripheral blood, or both) by World Health Organization (WHO) classification after failure of hypomethylating agent-based therapy.

Status: 
Recruiting
Study Date: 
Sun, 02/01/2015 to Fri, 09/01/2017
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Intervention: 
Drug: Tosedostat 120 mg PO once daily continuously for each 28 day treatment cycle Other Name: CHR-2797